QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fibrogens-cfo-juan-graham-planned-departure-date-is-december-15-2024

- SEC Filing

 fibrogen-q2-2024-gaap-eps-016-beats-026-estimate-sales-50641m-beat-34661m-estimate

FibroGen (NASDAQ:FGEN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 3...

 fibrogen-announces-topline-results-from-two-late-stage-pamrevlumab-pancreatic-cancer-studies-pamrevlumab-arm-of-precision-promisesm-study-in-metastatic-pancreatic-cancer-did-not-meet-primary-endpoint

Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Can...

 whats-going-on-with-fibrogen-stock-tuesday

FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational...

 fibrogen-stock-is-surging-after-the-bell-whats-going-on

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investiga...

Core News & Articles

FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combi...

 fibrogen-shares-climb-on-strong-q1-sales

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION